Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1977 Aug 31;54(1):35-8.
doi: 10.1007/BF00426538.

Antimuscarinic properties of antidepressants: dibenzepin (Noveril)

Antimuscarinic properties of antidepressants: dibenzepin (Noveril)

M Rehavi et al. Psychopharmacology (Berl). .

Abstract

The antimuscarinic potency of dibenzepin (Noveril) was estimated by measuring (a) central in vivo effects in mice (antihypothermia and antitremor, both induced by oxotremorine), (b) peripheral in vivo activity (mydriasis caused by systemic administration of the drug), (c) the effects of dibenzepin on isolated smooth muscle from guinea pig ileum, and (d) in vitro determination of the affinity constant of dibezepine toward the muscarinic binding sites in whole mouse-brain homogenate. The data allowed the construction of a normalized antimuscarinic potency scale for some of the common tricyclic antidepressants. With a value of 1 for scopolamine, the following relative anticholinergic potencies were calculated: dibenzepin--1/600, nortriptylne--1/300, imipramine - 1/200, and amitriptyline - 1/75. These values suggest an explanation for the absence of clinically detectable anticholinergic side effects during treatment of depression with high doses of dibenzepin. Structural and spatial interrelations among various tricyclic antidepressants and scopolamine are discussed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Biochem Pharmacol. 1973 Jan 1;22(1):73-84 - PubMed
    1. Eur J Pharmacol. 1976 Feb;35(2):245-52 - PubMed
    1. Arch Int Pharmacodyn Ther. 1966 Jun;161(2):423-30 - PubMed
    1. Biochem Pharmacol. 1977 Sep 1;26(17):1559-67 - PubMed
    1. Br J Pharmacol. 1974 Jul;51(3):399-403 - PubMed

LinkOut - more resources